Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

FOSAPREPITANT DIMEGLUMINE

FOSAPREPITANT DIMEGLUMINE

Standard Dose
EQ 150MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview FOSAPREPITANT DIMEGLUMINE is listed in Drugs@FDA under application 214683 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAPREPITANT DIMEGLUMINE Form and strength POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL Sponsor PIRAMAL CRITICAL Submission history Latest submission status date: 2023-05-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview FOSAPREPITANT DIMEGLUMINE is listed in Drugs@FDA under application 214683 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAPREPITANT DIMEGLUMINE Form and strength POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL Sponsor PIRAMAL CRITICAL Submission history Latest submission status date: 2023-05-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.